Table 2.

Incidence rates (IRs) for subtrochanteric or diaphyseal femur fracture per 1,000 person-years in the propensity score-matched population

	Bisphosphonates				Raloxifene/calcitonin
Outcomes	N patients	N events	Person- years	IR * (95% CI)	N patients	N events	Person- years	IR * (95% CI)
Primary (as treated) analysis
Subtrochanteric or diaphyseal femur fracture	17,028	57	39,095	1.46 (1.11–1.88)	16,787	47	32,836	1.43 (1.06–.89)
Subtrochanteric femur fracture	17,028	36	39,098	0.92 (0.66–1.3)	16,787	34	32,836	1.04 (0.73–1.43)
Diaphyseal femur fracture	17,028	24	39,095	0.61 (0.40–0.90)	16,787	13	32,836	0.40 (0.22–0.66)
Secondary (first exposure carried forward) analysis
Subtrochanteric or diaphyseal femur fracture	17,028	22	15,817	1.39 (0.89–2.07)	16,787	21	15,333	1.37
Subtrochanteric femur fracture	17,028	15	15,817	0.95 (0.55–1.53)	16,787	16	15,333	1.04 (0.62–1.66)
Diaphyseal femur fracture	17,028	8	15,817	0.51 (0.24–0.96)	16,787	5	15,333	0.33 (0.12–0.72)
Sensitivity(as treated with no lag period) analysis
Subtrochanteric or diaphyseal femur fracture	29,780	81	58,344	1.39(1.11–1.72)	29,743	72	46,959	1.53 (1.21–1.92)
Subtrochanteric femur fracture	29,780	41	58,347	0.70 (0.51–0.94)	29,743	45	46,936	0.96 (0.71–1.27)
Diaphyseal femur fracture	29,780	46	58,344	0.79 (0.58–1.04)	29,743	27	46,960	0.57 (0.39–0.83)

^*in 1,000 person-years, CI: confidence interval